Drug Trial Radar · NCT03492281
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
Last checked: Nov 20, 2026Latest source record: Mar 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,530
Actual
Start
Mar 26, 2018
Primary completion
Jan 10, 2019
Study completion Feb 4, 2019
Sponsor
- Lead sponsor
- Urovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Apr 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
Conditions
- Overactive Bladder
Interventions
vibegronDrug
single daily oral dose of vibegron 75 mg for 12 weeks
Vibegron placeboDrug
placebo to match vibegron (experimental drug)
Tolterodine Tartrate ERDrug
single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
Tolterodine placeboDrug
placebo to match tolterodine (active comparator)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) ParticipantsTime frame: Baseline (BL); Week 12
- CFB at Week 12 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet ParticipantsTime frame: Baseline; Week 12
Locations
215 sites in 6 countries. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama
Achieve Clinical Research
Birmingham, Alabama
Fundamental Research LLC
Gulf Shores, Alabama
Longwood Research
Huntsville, Alabama
Coastal Clinical Research Inc.
Mobile, Alabama
Clinical Research Consortium
Tempe, Arizona
Noble Clinical Research
Tucson, Arizona
Eclipse Clinical Research
Tucson, Arizona
Dream Team Clinical Research LLC
Anaheim, California
Hope Clinical Research
Canoga Park, California
Core Healthcare Group
Cerritos, California
Research Center of Fresno Inc.
Fresno, California
American Clinical Trials
Hawaiian Gardens, California
Marvel Clinical Research
Huntington Beach, California
Grossmont Center for Clinical Research
La Mesa, California
Prime-Care Clinical Research
Laguna Hills, California
Long Beach Clinical Trial Services Inc.
Long Beach, California
Long Beach Clinical Trials LLC
Long Beach, California
Downtown L.A. Research Center Inc.
Los Angeles, California
Urology Group of Southern California
Los Angeles, California
Tri Valley Urology Medical Group
Murrieta, California
Northern California Research
Sacramento, California
San Bernadino Urological Associates
San Bernardino, California
Artemis Institute for Clinical Research
San Diego, California
WR MCCCR
San Diego, California
Artemis Institute for Clinical Research
San Marcos, California
Empire Clinical Research
Upland, California
Bayview Research Group LLC
Valley Village, California
Horizons Clinical Research Center
Denver, Colorado
Lynn Institute of Denver
Denver, Colorado
Clinical Research Consulting LLC
Milford, Connecticut
Coastal Connecticut Research LLC
New London, Connecticut
Chase Medical Research, LLC
Waterbury, Connecticut
Innovative Medical Research of South Florida Inc.
Aventura, Florida
PAB Clinical Research
Brandon, Florida
Innovative Research of West FL Inc.
Clearwater, Florida
Universal Medical and Research Center LLC
Coral Gables, Florida
Top Medical Research Inc.
Cutler Bay, Florida
Avail Clinical Research
DeLand, Florida
Jesscan Medical Research
Delray Beach, Florida
Showing 40 of 215 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.